<div id="readability-page-1"><p>Polar Asset Management Partners Inc. cut its holdings in shares of  Penumbra, Inc. (NYSE:PEN - Free Report) by 67.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor  owned 40,259 shares of the company's stock after selling 81,867 shares during the period. Polar Asset Management Partners Inc. owned about 0.10% of Penumbra worth $10,766,000 as of its most recent SEC filing.</p><ul><li>3 Mid-Cap Medical Stocks Outperforming the Market</li></ul><p>Several other large investors also recently modified their holdings of the business. Mercer Global Advisors Inc. ADV grew its stake in  Penumbra by 41.8% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 1,760 shares of the company's stock worth $418,000 after purchasing an additional 519 shares in the last quarter.  BNP Paribas Financial Markets grew its stake in  Penumbra by 59.3% in the fourth quarter. BNP Paribas Financial Markets now owns 6,523 shares of the company's stock worth $1,549,000 after purchasing an additional 2,429 shares in the last quarter.  Bank of America Corp DE grew its stake in  Penumbra by 19.9% in the fourth quarter. Bank of America Corp DE now owns 346,528 shares of the company's stock worth $82,293,000 after purchasing an additional 57,421 shares in the last quarter.  Captrust Financial Advisors acquired a new position in  Penumbra in the fourth quarter worth about $343,000.  Finally, Brevan Howard Capital Management LP acquired a new position in  Penumbra in the fourth quarter valued at approximately $253,000. 88.88% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Penumbra Price Performance</h2><p>Shares of NYSE:PEN opened at $279.60 on Friday. Penumbra, Inc. has a 12 month low of $184.80 and a 12 month high of $310.00. The stock has a market cap of $10.90 billion, a price-to-earnings ratio of 74.36, a PEG ratio of 2.43 and a beta of 0.45. The stock's 50 day moving average price is $248.82 and its 200 day moving average price is $265.55. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 4.04. </p><ul><li>Are These Medical Device Makers Getting Ready To Rally? </li></ul><p>Penumbra (NYSE:PEN - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.05. The firm had revenue of $339.46 million for the quarter, compared to analyst estimates of $327.37 million. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. The firm's quarterly revenue was up 13.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.64 earnings per share.  Penumbra has set its FY 2025 guidance at  EPS. Equities research analysts anticipate that  Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year. </p><h2>Insider Activity</h2><p>In other news, EVP Johanna Roberts sold 600 shares of the business's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $252.70, for a total transaction of $151,620.00. Following the transaction, the executive vice president directly owned 66,057 shares in the company, valued at $16,692,603.90. The trade was a 0.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Adam Elsesser sold 16,150 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $233.16, for a total transaction of $3,765,534.00. Following the transaction, the chief executive officer owned 146,258 shares in the company, valued at approximately $34,101,515.28. This represents a 9.94% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 128,073 shares of company stock valued at $31,968,224. 4.20% of the stock is currently owned by company insiders. </p><h2>Analyst Ratings Changes</h2><p>PEN has been the subject of a number of research reports. Robert W. Baird lifted their target price on Penumbra from $283.00 to $285.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, July 30th. Citigroup decreased their target price on Penumbra from $320.00 to $285.00 and set a &#34;neutral&#34; rating for the company in a research note on Wednesday, July 9th. William Blair upgraded Penumbra to a &#34;strong-buy&#34; rating in a research note on Friday, July 18th. Truist Financial  set a $310.00 target price on Penumbra and gave the company a &#34;buy&#34; rating in a research note on Wednesday, July 30th. Finally, Wall Street Zen upgraded Penumbra from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, August 30th. One analyst  has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $302.93.</p><p><b>View Our Latest Research Report on Penumbra</b></p><h2>Penumbra Profile</h2> (Free Report)<p>Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Penumbra</li><li>What is a Secondary Public Offering? What Investors Need to Know</li><li>Here's What Separates Oklo From the Rest of the Nuclear Startups </li><li>Low PE Growth Stocks: Unlocking Investment Opportunities</li><li>Why Marvell’s 19% Drop Could Be a Big Buy-the-Dip Opportunity</li><li>Using the MarketBeat Dividend Yield Calculator</li><li>Daqo New Energy: Solar Monopoly Launches $100M Buyback</li></ul><p><strong>Want to see what other hedge funds are holding PEN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBFTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBFTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Penumbra Right Now?</h2><p>Before you consider Penumbra, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list.</p><p>While Penumbra currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Polar Asset Management Partners Inc. reduced its stake in Penumbra, Inc. by 67% in Q1, now holding 40,259 shares valued at approximately $10.77 million. Other investors, including Mercer Global Advisors and BNP Paribas, increased their stakes. Penumbra's stock opened at $279.60, with a market cap of $10.90 billion. The company reported Q2 earnings of $0.86 per share, exceeding estimates, and anticipates a FY 2025 EPS of 3.67. Insider selling activity was noted, with executives reducing their holdings.</p>

Polar Asset Management Partners Inc. Cuts Stake in Penumbra, Inc. $PEN